UK stocks notch two-month highs as U.S. inflation cools



(For a Reuters live blog on U.S., UK and European stock markets, click

or type LIVE/ in a news window.)

*

AstraZeneca jumps on raising earnings forecast

*

Centrica to buy back up to 5% of shares

*

U.S. October inflation up less than expected

*

FTSE 100 up 1.1%, FTSE 250 gains 3.9%

By Johann M Cherian and Sruthi Shankar

Nov 10 (Reuters) -

The UK's main stock indexes closed at near two-month highs on Thursday, joining a global rally sparked by cooling U.S. inflation that drove expectations of smaller interest rate hikes by the Federal Reserve.

The FTSE 100 .FTSE rose 1.1% to its strongest close since Sept. 13. However, a rally in the pound GBP=D3 checked further gains in the exporter-heavy index.

The domestically focussed FTSE 250 index .FTMC jumped 3.9% to post its biggest percentage gain in eight months.

The rally came as Wall Street's main indexes soared after data showed U.S.consumer prices rose less than expected in October, spurring bets that the Fed will hike interest rates by a smaller 50 basis points in December.

"U.S. inflation data has provided a welcome shot in the arm for markets, with the declines seen across both headline and core inflation bringing the kind of optimism that has been lacking without seeing non-energy related inflation turn lower," said Joshua Mahony, senior market analyst at online trading platform IG.

UK equities have climbed along with global stocks in recent weeks as hopes that the U.S. central bank will slow its pace of rate hikes and better-than-expected earnings offset data signalling a weakening domestic economy.

The midcap index has rallied nearly 17% off its October lows, but is still down as much on a year-to-date basis. The blue-chip FTSE 100 has bounced 8% from its trough, erasing nearly all of its annual declines.

A survey on Thursday showed British house prices fell for the first time in 28 months in October and rising mortgage costs threatened to put further pressure on the property market.

Among single stocks, AstraZeneca AZN.L rose 2.9% after the drugmaker raised its full-year adjusted earnings forecast on a boost from sales of its roster of cancer drugs.

Power company Centrica CNA.L climbed 7.4% after it forecast its annual adjusted earnings per share outlook to be at the top end of analysts' expectations, and announced a share buyback of up to 5% of its share capital.

WH Smith SMWH.L added 5.1% after the company, which sells everything from books and sandwiches to Bluetooth headphones, reinstated dividends and posted an annual profit.
Reporting by Johann M Cherian in Bengaluru; Editing by Sherry Jacob-Phillips, Uttaresh.V and Jonathan Oatis

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.